A popular antidepressant, often known by the brand name Cymbalta, was recalled last week due to the presence of a potentially cancer-causing chemical. More than 233,000 bottles of duloxetine capsules ...

The results of the current investigation are based on the initial 12-week, open-label acute treatment phase of a randomized withdrawal study of duloxetine in the prevention of relapse of MDD. Results ...

A nationwide recall of more than 233,000 bottles of duloxetine, an anti-depressant, has been announced by the Food and Drug Administration for possibly containing a chemical increasing the risk of ...

The U.S. Food and Drug Administration announced a Class II recall for more than 7,100 bottles of Duloxetine — a generic antidepressant for Cymbalta — due to a cancerous chemical. A voluntary recall ...

Over 8 million U.S. adults take antidepressants to treat mild to moderate depression, anxiety and, in some cases, chronic pain. A recent Food and Drug Administration (FDA) recall of a commonly ...

The analytic cohort included 57,086 older adults initiating treatment with gabapentin or duloxetine. HealthDay News — Incident use of gabapentin is not associated with an increase in fall-related ...

INDIANAPOLIS -- Eli Lilly and Co. said yesterday that it received Food and Drug Administration approval to expand the use of its fastest-growing drug, the antidepressant Cymbalta. Regulators approved ...

Findings seen in older adults with diabetic neuropathy, postherpetic neuralgia, or fibromyalgia. (HealthDay News) — Incident use of gabapentin is not associated with an increase in fall-related ...